NASDAQ · CUE
Cue Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CUE: Nov 11, 2026
Cue Biopharma, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-4.04. The reported EPS for the same quarter last year was $-2.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-4.04 | $-4.04 | $-4.04 | 1 |
| Dec 2026 | $-2.83 | $-2.83 | $-2.83 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel- MarketBeat · Sep 28, 5:02 AM EDTCue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU ResponseCue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-contr
- RTTNews · Sep 20, 2:37 PM EDTCue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up(RTTNews) – Cue Biopharma (CUE) on Sunday announced positive topline results from a Phase 2a study of CUE-221 in patients with moderate to severe chronic spontaneous urticaria, also known as chronic hives. The drug met both the primary endpoint and a key secondary endpoint, suppo
- Fintel · Sep 18, 12:18 PM EDTB. Riley Securities Initiates Coverage of Cue Biopharma with BuyListings: (NASDAQCM:CUE) (DB:1UC0)Fintel reports that on September 18, 2026, B. Riley Securities initiated coverage of Cue Biopharma (NASDAQCM:CUE) with a Buy recommendation.
- RTTNews · Aug 17, 6:15 AM EDTCue Biopharma Q2 Net Loss Widens; Expects Phase 2 Data For CUE-221 In CSU By End Of Q3 2026(RTTNews) – Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss while revenue increased primarily due to a milestone payment from its collaboration with Boehringer Ingelheim.
- RTTNews · Aug 4, 2:22 AM EDTCue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress(RTTNews) – Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, announced the appointment of James Ahlers as Chief Financial Officer (CFO), effective immediately.
- RTTNews · Jul 13, 8:51 AM EDTCue Biopharma Appoints Dominic Borie As CMO(RTTNews) – Cue Biopharma, Inc. (CUE), on Monday, announced that it appointed Dominic Borie as Chief Medical Officer and Head of Research & Development, effective immediately.
- RTTNews · Jul 13, 7:17 AM EDTBiotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH(RTTNews) – The following biotech stocks touched a 52-wek high on July 10, 2026, driven by key catalysts like encouraging regulatory updates and quarterly results.
- RTTNews · Jul 10, 2:32 AM EDTCue Biopharma Announces $50 Million Private Placement; Stock Up(RTTNews) – Cue Biopharma, Inc. (CUE) announced it has entered into a securities purchase agreement with accredited investors for a private placement of 1,418,071 shares of common stock at $33.21 per share. Certain investors also received pre-funded warrants to purchase up to 87,
- RTTNews · Jun 2, 10:11 PM EDTTop Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL(RTTNews) – Tuesday's top gainers in the healthcare sector included Bluejay Diagnostics, which inked a strategic partnership with Argonaut; Picard Medical, which is advancing its next-generation Emperor Total Artificial Heart; and Cingulate, which rallied despite a regulatory set
- RTTNews · Apr 30, 10:52 PM EDTCue Unveils $30 Mln Private Placement, License Agreement With Ascendant; Names New CEO; Stock Up(RTTNews) – Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company, announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement for gross proceeds of approximately $30 million and has appointed Shao-L
- Fintel · Apr 27, 11:21 PM EDTCue Biopharma (CUE) Price Target Increased by 2,900.00% to 122.40The average one-year price target for Cue Biopharma (NasdaqCM:CUE) has been revised to $122.40 / share. This is an increase of 2,900.00% from the prior estimate of $4.08 dated April 12, 2026. The price target is an average of many targets provided by analysts.
- RTTNews · Apr 22, 10:01 AM EDTCue Biopharma Implements 1-for-30 Reverse Split; Stock Down(RTTNews) – Cue Biopharma, Inc. (CUE) announced it will implement a 1-for-30 reverse stock split of its common shares, effective April 23, 2026. The move, approved at the company's Annual Meeting earlier this month, was authorized by the Board to increase the per-share market pri
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cue Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.